Daiichi Sankyo Logo Vector
Daiichi Sankyo is a global pharmaceutical company with headquarters in Tokyo, Japan. The company has a long history of innovation, dating back to its founding in 1881. Today, Daiichi Sankyo is a leading developer of innovative therapies for a variety of diseases, including cancer, cardiovascular disease, and diabetes.
Daiichi Sankyo's pipeline of product candidates includes several promising new drugs, such as:
Enhertuzumab: A monoclonal antibody for the treatment of gastric, esophageal, and lung cancer.
Entresto: A combination of an angiotensin receptor blocker (ARB) and a neprilysin inhibitor (NEP inhibitor) for the treatment of heart failure.
Farxiga: A sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
